Less chemo plus antibody therapy for high-risk neuroblastoma in children
Treatments studied
Part of Cancer clinical trials.
This study tests whether giving fewer chemotherapy drugs along with other targeted therapies (monoclonal antibodies) works well for children with high-risk neuroblastoma. It aims to reduce side effects while still treating the cancer effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must have been diagnosed with neuroblastoma.
- The neuroblastoma must be high-risk (such as having a MYCN gene change or being stage M in children over 18 months).
- Your child should have had at most one cycle of chemotherapy for high-risk neuroblastoma before joining.
- Your child must be under 19 years old.
- Your child cannot have severe organ problems (like kidney or heart issues) unless they are directly caused by the tumor or its treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy and immunotherapy as a first treatment for children and young adults with high-risk neuroblastoma. The goal is to see if this approach can improve outcomes.
This Phase 1 trial tests a combination of dinutuximab beta (an immunotherapy) and chemotherapy in children with high-risk neuroblastoma that did not respond to standard treatment or has come back or progressed. It aims to see how well the treatment works and how safely it can be given in this situation.
This trial tests a new drug combination (dinutuximab-beta plus chemotherapy) for children and young adults with newly diagnosed high-risk neuroblastoma. The goal is to see if adding this targeted therapy to standard chemo improves outcomes.
This trial tests adding a targeted drug called dinutuximab to standard chemotherapy, surgery, and a stem cell transplant for children and young adults with a new diagnosis of high-risk neuroblastoma. The goal is to see if this combination helps more patients stay in remission.
This Phase 3 study tests whether adding either a targeted drug (lorlatinib) or a radioactive treatment (131I-MIBG) to intensive chemotherapy improves outcomes for children with high-risk neuroblastoma. It may help by aiming at tumor cells more directly alongside standard treatment.
This trial tests a personalized treatment plan for children with high-risk neuroblastoma, a type of nerve tissue cancer. It aims to improve outcomes by tailoring therapy based on each child's tumor characteristics and response to prior treatment.
Hear when a new High-Risk Neuroblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.